Abstract
AIDS:
In an attempt to simplify antiretroviral regimens, several studies evaluated the use of either indinavir or nelfinavir in twice-daily dosing regimens. Results from a study testing nelfinavir at 750 mg and 1250 mg dosing levels are presented indicating some success with twice-daily therapy, particularly at the 1250 mg level. The indinavir study also shows successful viral load drops using twice-daily regimens. A twice-daily regimen might be considered for patients unable or unwilling to adhere to the thrice-daily regimen. However, long term follow-up studies are needed before switching to twice-daily therapy.
MeSH terms
-
Anti-HIV Agents / administration & dosage*
-
Anti-HIV Agents / pharmacokinetics
-
Anti-HIV Agents / therapeutic use
-
Area Under Curve
-
CD4 Lymphocyte Count
-
Drug Administration Schedule
-
HIV Infections / drug therapy*
-
HIV Protease Inhibitors / administration & dosage*
-
HIV Protease Inhibitors / pharmacokinetics
-
HIV Protease Inhibitors / therapeutic use
-
Half-Life
-
Humans
-
Nelfinavir / administration & dosage*
-
Nelfinavir / pharmacokinetics
-
Nelfinavir / therapeutic use
-
Patient Compliance
-
Reverse Transcriptase Inhibitors / administration & dosage*
-
Reverse Transcriptase Inhibitors / pharmacokinetics
-
Reverse Transcriptase Inhibitors / therapeutic use
-
Viral Load
Substances
-
Anti-HIV Agents
-
HIV Protease Inhibitors
-
Reverse Transcriptase Inhibitors
-
Nelfinavir